Leukemias | Clinical

Venugopal Considers BTK and BCL2 Inhibitors in Patient With CLL

July 22, 2021

Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.

Using CAR T-Cell Therapy Earlier May Produce More Benefit in ALL

July 08, 2021

Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.

FDA Approves Rylaze for Subsets of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

July 01, 2021

The FDA has granted approval to Rylaze for use within a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products that are traditionally used.

Ponatinib Plus Blinatumomab Shows Potential as a Chemo-Free Option for Ph+ ALL

June 04, 2021

Early results of a phase 2 study show that the efficacy achieved with the combination of ponatinib and blinatumomab represents a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.